Loading
Electra Therapeutics
A US company making antibodies against SIRP proteins to remove overactive immune cells. Its lead drug is mainly for a dangerous inflammatory condition called sHLH, and it is also in an early trial for T-cell and NK-cell blood cancers that have come back.
Also called: Electra Therapeutics, Inc.Electra Therapeutics Inc.
Overview
Electra Therapeutics develops antibodies directed at signal regulatory proteins (SIRP) that it says selectively deplete activated, disease-driving immune cells. Its lead antibody, ipsoprubart (ELA026), binds SIRP-alpha and SIRP-beta1 on myeloid cells and SIRP-gamma on T cells. It is in a registrational Phase 2/3 programme as first-line treatment for secondary haemophagocytic lymphohistiocytosis (sHLH), a hyperinflammatory condition whose largest subtype, the company says, is malignancy-associated HLH, and in a Phase 1 trial in relapsed or refractory T-cell and NK-cell malignancies (NCT07465835, recruiting since February 2026). A second antibody, ELA822, is aimed at immune-mediated diseases. The IPO prospectus states the company was incorporated in Delaware in October 2018 as a wholly owned subsidiary of Star Therapeutics. Its Form 8-K reports that the IPO closed on 21 September 2026 at $15.00 a share for gross proceeds of about $350.0 million, with the stock on the Nasdaq Global Select Market under ETRA.
Headquarters
South San Francisco, CA, US
Scorecard
All companies#622of 1706 companies, score 5
- phase 1/2 +1
- targets +2
- modalities +2
0 approved, 0 in phase 3, 1 earlier, 1 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsPublic
Investors
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| IPO · 23,333,334 shares at $15.00; gross proceeds of approximately $350.0 million before underwriting discounts and expenses. | 2026 | $350M | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Biotech · NASDAQ: ETRA
Stage
Public
Website
Founded
2018
Products
1Phase 1Monoclonal antibody
Ipsoprubart is an experimental antibody from Electra Therapeutics, in phase 1 trials for relapsed or refractory T-cell and NK-cell cancers.
Notes
- Cancer ids left empty: the trial condition is 'T Cell Malignancies' without a named subtype, and sHLH is not a cancer.
- NCT07465835 (Phase 1, T/NK cell malignancies) and NCT05416307 (Phase 2/3, sHLH) were confirmed through the ClinicalTrials.gov v2 API; neither is a trial record in OnCo yet.
- OrbiMed's portfolio page lists Electra with a first investment dated 02/09/2022; the prospectus names OrbiMed Private Investments VII as a holder with a board designee.
Connected
7Similar pages
- CompanyAlentis Therapeutics
Shares OrbiMed, RA Capital Management, Monoclonal antibodies.
- CompanyAdela
Shares OrbiMed, RA Capital Management.
- CompanySolstice Oncology
- CompanyStipple Bio
- CompanyOttimo Pharma
Shares OrbiMed, Monoclonal antibodies.
- CompanyTerremoto Biosciences
Shares OrbiMed, RA Capital Management.
- CompanyAdcendo
Shares OrbiMed, RA Capital Management.
fronts
technologies
targets
drugs
Phase 1Monoclonal antibody
companies
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
electra-therapeutics.com · 3
sec.gov · 3
ClinicalTrials.gov · 1
orbimed.com · 1
racap.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/